Literature DB >> 12356284

Study on biodegradable microspheres containing recombinant interferon-alpha-2a.

Shaobing Zhou1, Xianmo Deng, Shuiying He, Xiaohong Li, Wenxiang Jia, Dapeng Wei, Zairong Zhang, Jihui Ma.   

Abstract

In this work, a new microsphere delivery system comprising calcium alginate microcores surrounded by a biodegradable poly-DL-lactide-poly(ethylene glycol) (PELA) coat was designed to improve the loading efficiency and stability of peptide drugs. Recombinant interferon (IFN)-alpha-2a, used as a model peptide drug, was efficiently entrapped within the alginate microcores using a high-speed stirrer and then microencapsulated into PELA copolymer using a water-in-oil-in-water solvent extraction method. Microspheres were characterized in terms of morphology, size and distribution, encapsulation efficiency, IFN biological activity retention and in-vitro peptide release. The IFN potency test showed that IFN entrapped in the core-coated microspheres could retain its biological activity during the encapsulation and release procedure. The release profiles were determined by the measurement of peptide presenting in the release medium at various intervals. The IFN potency, calculated by the Wish cells/vesicular stomatitis virus system, was used to determine IFN biological activity. The results showed that the core-coated microspheres could stabilize IFN in the PELA matrix. We compared the new deliverysystem with conventional microsphere delivery systems based on biodegradable poly-DL-lactide and poly-DL-lactide-poly(ethylene glycol). The core-coated microspheres had the highest amount of entrapment, encapsulation efficiency and biological activity retention. The extent of burst release (14%) from the core-coated microspheres in the initial protein release was much lower than the 31% burst release from the conventional microspheres. In conclusion, this work presents a new approach for water-soluble macromolecular drugs delivery (e.g. protein, peptide drugs, vaccines).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356284     DOI: 10.1211/002235702320402143

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

Review 1.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 2.  Long-term delivery of protein therapeutics.

Authors:  Ravi Vaishya; Varun Khurana; Sulabh Patel; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2014-09-24       Impact factor: 6.648

Review 3.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

4.  CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.

Authors:  Erica L Johnson; Rajesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard; Shailesh Singh
Journal:  J Ovarian Res       Date:  2010-06-17       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.